NCT04617925 - A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 26, 2021

Primary Completion Date

July 17, 2025

Study Completion Date

July 17, 2025

Conditions

AL Amyloidosis

Interventions

DRUG

Belantamab mafodotin

Belantamab mafodotin will be administered as a monotherapy intravenously at a 2.5 mg/kg calculated dose

Trial Locations (6)

"Fondazione I.R.C.C.S Policlinico San Matteo", Pavia

University Hospital Heidelberg, Heidelberg

Centre hospitalier Universitaire de Limoges -, Limoges

"General Hospital of Athens Alexandra", Athens

UMC Utrecht, Utrecht

Royal Free Hospital - London,, London